Pall — Q1 FY2013 Earnings Presentation
23 slides from Pall's earnings presentation, Nov 30, 2012
Slide 1: Q1 FY 2013 Financial Results
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2012 Pall Corpor
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the first quarter of fiscal year 2013 are preliminary until the Company's Form 10-Q is filed with the Securities and Exchange Commission o
Slide 3: Conference Call Replay Info
3 Conference Call Replay Info Toll-Free: 855.859.2056 International: 404.537.3406 Conference ID: 68728759 Internet: www.pall.com/investor
Slide 4: Agenda
4 Agenda Q1 Financial Performance FY 2013 Outlook Update Q&A All remarks in this presentation are on a “Continuing Operations” basis, which excludes the results of the Blood product line divestiture, unless indicated otherwise.
Slide 5: Q1 Overview
5 Q1 Overview Continued performance in Life Sciences Slower Industrial end-markets Impact of cost savings initiatives and productivity improvements Ramp up focused R&D spend Team responded well to Pall Industrial sluggish demand
Slide 6: First Quarter Sales by Segment
6 Life Sciences Consumables $276 +4.0% Industrial Consumables $276 -3.4% Industrial Systems $52 -4.3% Life Sciences Systems $24 +2.1% 44% 44% 8% 4% First Quarter Sales by Segment Life Sciences: $300 (+3.8%) Industrial: 328 (-3.5%) Total Sales: $628 (-0.1%) Dollars in millions Percentages outside pie
Slide 7: Life Sciences Q1 FY 2013 Sales & Orders
7 Life Sciences Q1 FY 2013 Sales & Orders Sales Consumables BioPharmaceuticals +7.0% − Strength in the biotech sector Food and Beverage -3.1% − Up slightly excluding Italy divestiture − Sluggishness in beer and wine production levels Medical -0.5% Systems Increase in BioPharm largely offset
Slide 8: Industrial Q1 FY 2013 Sales & Orders
8 Industrial Q1 FY 2013 Sales & Orders Sales Consumables Process Technologies -3.6% − Decreased sales to Machinery & Equipment OEMs − Increased sales in Energy Market Aerospace +2.7% − Military sales were flat and Commercial +5.0% Microelectronics -7.3% − Low utilization rate at chip makers −
Slide 9: Q1 FY 2013 Sales & Orders by Region
9 $0 $100 $200 $300 FY 12 FY 13 FY 12 FY 13 FY 12 FY 13$211 $187 -10.6% $259 $239 -0.7% $197 $187 -3.9% Q1 FY 2013 Sales & Orders by Region Dollars in millions Sales and orders changes exclude FX Americas Sales Mature markets grew ~ +5% (+2% organic growth) Latin America ~ -20% Orders Orders i
Slide 10: Financial Summary
10 Revenue % Growth Excluding FX Q1 FY 2012 Q1 FY 2013 Financial Summary (a) See Reconciliation of Non-GAAP Financial Measures to their GAAP Counterparts in Appendix (b) From continuing operations Dollars in Millions, except EPS data Operating Profit Margin Increase in Basis Points Q1 FY 2012 Q1 FY
Slide 11: Segment Performance
11 0% 30% 60% Q1 Q1 0% 25% 50 Q1 Q1 12.5% Gross Margin Segment Margin Segment Performance Life Sciences Q1 GM impacted by FX headwinds. Favorable consumables mix partly offset. SG&A ~ + 9% ex FX and +140 basis points as a % of sales 58.7% -40 bps 59.1% 23.3% -310 bps 26.4% Gross Margin Segment M
Slide 12: Cash Flow and Working Capital
12 Cash Flow and Working Capital Q1 FY13 Q1 FY12 Operating Cash Flow 39$ 78$ CapEx (23) (56) Free Cash Flow 16$ 22$ Other Significant Sources/(Uses) of Cash: Proceeds from sale of assets 536$ 20$ Acquisition of businesses - (28) Dividends (24) (20) Repayment under Financing Facilities (75) (70) Stoc
Slide 13: FX Risk
13 1.25 1.29 1.30 1.44 1.36 1.42 1.33 1.30 1.31 1.35 1.33 1.33 1.24 1.24 1.23 0.79 0.80 0.81 0.89 0.87 0.88 0.85 0.84 0.84 0.85 0.83 0.81 0.80 0.80 0.78 0.70 1.15 1.60 Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun Jul € to USD FY13 € to USD FY12 € to GBP FY13 € to GBP FY12 FX Risk US D a n d G BP Eq
Slide 14: FY 2013 Business Outlook
14 FY 2013 Business Outlook Americas Europe Asia BioPharm Medical MicroE Process Aerospace F&B Current Expectation(1) Life Sciences continues to perform Industrial end-market weakness generally MicroE recovery delayed Better Neutral Worse (1) Compared to original expectation
Slide 15: FY 2013 Business Outlook (cont'd)
15 Overall Revenue Flat to low single-digit growth Pro Forma EPS $2.95 – $3.15 Represents growth of 5% – 13% Negative FX impact of 8% FY 2013 Business Outlook (cont’d) Segment Sales Life Sciences: Mid to high single-digit growth Industrial: Low to mid single-digit decline Cash Flow Cap
Slide 16: Appendix
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2012 Pall Corpor
Slide 17: Q1 Earnings and FY 2013 Estimates from Continuing Operations
17 Appendix: Q1 Earnings and FY 2013 Estimates from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 0.77$ 0.51$ 3.14$ Discrete Items: ROTC after pro forma tax effect 0.03 0.15 0.03 Tax Adjustments (0.09) - (0.09) Interest Adjustm
Slide 18: Q1 Life Sciences Sales By Market & Technology
18 Appendix: Q1 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q1 FY13 Q1 FY13 Estimated Impact of FX Q1 FY13 Estimate Excluding FX Q1 FY12 % Change Excluding FX Consumables Sales: BioPharmaceuticals 187.2$ (8.4)$ 195.6$ 182.9$ 7.0% Food & Beverage 41.6 (2.2
Slide 19: Q1 Industrial Sales By Market & Technology
19 Appendix: Q1 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q1 FY13 Q1 FY13 Estimated Impact of FX Q1 FY13 Estimate Excluding FX Q1 FY12 % Change Excluding FX Consumables Sales: Process Technologies 150.0$ (5.3)$ 155.3$ 161.0$ -3.6% Aerospace 55.9 (1.0) 56.9
Slide 20: Q1 Sales by Segment and Region
20 Appendix: Q1 Sales by Segment and Region Reconciliation of Non-GAAP Financial Measures Q1 FY13 Q1 FY13 Estimated Impact of FX Q1 FY13 Estimate Excluding FX Q1 FY12 % Change Excluding FX Life Sciences Sales: Americas 97.8$ (0.7)$ 98.5$ 90.7$ 8.6% Europe 143.7 (11.5) 155.2 153.9 0.8% Asia 58.5 (1.2
Slide 21: Q1 Orders by Technology
21 Appendix: Q1 Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in millions Q1 FY13 Q1 FY13 Estimated Impact of FX Q1 FY13 Estimate Excluding FX Q1 FY12 % Change Excluding FX Life Sciences Orders: Consumables 288.8$ (13.2)$ 302.0$ 281.4$ 7.3% Systems 21.4 (0.9) 22.3 27.0 -
Slide 22: Q1 Operating Profit
22 Appendix: Q1 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q1 FY13 Q1 FY12 Life Sciences segment profit 69.8$ 79.7$ Industrial segment profit 52.8 43.6 Total segment profit 122.6$ 123.3$ General corporate expenses (14.1) (15.7) Ope ating profit 108.5$ 107.6$ % of
Slide 23: www.pall.com/green
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2012 Pall Corpor